Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol

Diabetes Care. 2004 Sep;27(9):2241-2. doi: 10.2337/diacare.27.9.2241.

Authors

Lena Normén¹, Jiri Frohlich, Julio Montaner, Marianne Harris, Tom Elliott, Greg Bondy

Affiliation

¹ Canadian HIV Trials Network, Pacific Region, Vancouver, British Columbia, Canada.

PMID: 15333491
DOI: 10.2337/diacare.27.9.2241

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cholesterol, HDL / blood*
Cholesterol, HDL / drug effects
Diabetes Complications / blood
Diabetes Complications / drug therapy
Diabetes Mellitus / blood
Diabetes Mellitus / drug therapy*
Female
Fenofibrate / therapeutic use*
HIV Seropositivity / blood
Humans
Hypoglycemic Agents / therapeutic use*
Hypolipidemic Agents / therapeutic use*
Lipids / blood
Male
Middle Aged
Retrospective Studies
Rosiglitazone
Thiazolidinediones / therapeutic use*

Substances

Cholesterol, HDL
Hypoglycemic Agents
Hypolipidemic Agents
Lipids
Thiazolidinediones
Rosiglitazone
Fenofibrate